ProShare Advisors LLC Increases Stake in Haemonetics Co. (NYSE:HAE)

ProShare Advisors LLC raised its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 40.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,486 shares of the medical instruments supplier's stock after purchasing an additional 4,771 shares during the period. ProShare Advisors LLC's holdings in Haemonetics were worth $1,287,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Janney Montgomery Scott LLC acquired a new stake in shares of Haemonetics in the fourth quarter worth approximately $402,000. KBC Group NV lifted its holdings in Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 712 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Haemonetics by 36.1% during the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after purchasing an additional 2,680 shares during the last quarter. Boston Trust Walden Corp grew its holdings in shares of Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after buying an additional 106,114 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Haemonetics in the fourth quarter valued at about $319,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Ratings Changes

HAE has been the subject of several research reports. Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Needham & Company LLC cut their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. JMP Securities reissued a "market outperform" rating and set a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Finally, Raymond James restated a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Trading Down 1.1%

HAE stock traded down $0.78 during midday trading on Wednesday, hitting $67.21. 40,932 shares of the company's stock were exchanged, compared to its average volume of 680,476. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $94.99. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $3.23 billion, a PE ratio of 26.49, a P/E/G ratio of 1.11 and a beta of 0.32. The business has a 50-day simple moving average of $63.22 and a two-hundred day simple moving average of $70.72.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company's revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.90 EPS. On average, sell-side analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.